#Netherlands #Breast Cancer #ScreenPoint Medical #Biomediq A/S #Nijmegen

ScreenPoint Medical Enhances Breast Cancer Risk Assessment with Biomediq Acquisition

In a significant move to improve breast cancer risk evaluation, ScreenPoint Medical has announced the acquisition of Biomediq A/S, a pioneering research company dedicated to the development of quantitative imaging biomarkers. This partnership, following years of collaboration, is expected to integrate Biomediq's innovative technology into ScreenPoint's leading breast cancer AI system, Transpara.

The technology developed by Biomediq focuses on the automated assessment of 2D and 3D mammograms, specifically identifying potential breast cancer risks by analyzing mammographic texture. This Biomarker, associated with the heterogeneity of breast tissue, serves as a predictive tool for both short- and long-term breast cancer risk. The synergy between Transpara's lesion detection capabilities and Biomediq's advanced texture analysis promises to refine the precision of breast cancer assessments significantly.

Recent findings published in the journal Radiology highlighted this integration's potential, showcasing improved risk prediction through combined analyses of volumetric density and quantitative texture. The lead author of this pivotal study, Dr. Andreas D. Lauritzen, is set to join the ScreenPoint team to expedite the development of risk assessment capabilities further.

Transpara stands as one of the most clinically validated breast AI applications, having been utilized globally to assist radiologists in early cancer detection while reducing recall rates. The recent update, Transpara 2.1, showcases refined algorithms built on insights from renowned global practitioners, enhancing automated breast density assessment and robust temporal comparisons of mammograms. This capability enables radiologists to analyze current studies against historical cases over multiple years, marking a substantial advancement in the field of radiology.

Professor Nico Karssemeijer, co-founder and Chief Scientific Officer at ScreenPoint Medical, remarked on the significance of this acquisition: "Risk-stratified screenings have long been proposed to optimize patient care and resource use. We look forward to integrating Biomediq's technology to expand Transpara's capabilities, marking a critical step towards accurate and consistent breast cancer detection and treatment for women everywhere."

Moreover, Professor Mads Nielsen, co-founder of Biomediq, noted the collaborative efforts that led to this acquisition, emphasizing a shared vision of improving women's healthcare through advanced screening technology. He will continue to provide advisory support to the expanded ScreenPoint team, ensuring that both companies benefit from their combined expertise.

With over 35 peer-reviewed publications, Transpara is distinguished as the only breast AI algorithm extensively evaluated across diverse real-world screening populations. Research has shown that utilizing Transpara can lead to the early detection of interval cancers by up to 45%, all while optimizing workflow and alleviating radiologists' workloads.

In closing, this acquisition exemplifies a significant step forward in the field of breast cancer screening, ushering in a new era of innovation that could transform how breast cancer risks are monitored and managed. ScreenPoint Medical aims to harness these advanced imaging technologies to foster enhanced diagnostic accuracy and improve patient outcomes worldwide.

For more information, visit ScreenPoint Medical's publication page.